ReSpire · Respirable Advanced Therapeutics for Cystic Fibrosis & other Lung Diseases

Via the SME Instrument OmniSpirant Ltd will mature its stem cell exosome-packaged gene therapy with lung mucuspenetration properties which will be more effective (improved lung function, reversal of lung damage and superior CFTRgene expression and function) and also be applicable to 100% of the CF global population. This approach, using a combinedpatent pending exosome surface engineering for enhanced mucus penetration and cell transfection with a tailored vibratingmesh nebulisation aerosol delivery method will provide a unique, potentially disruptive, therapeutic modality for CF and manyother lung diseases with high unmet medical need.Our competitive advantage and Unique Selling Points lower current effectiveness barriers and make the OmniSpirantexosome technology the only therapeutic delivery method that could provide a truly effective treatment for CF, thusimproving both survival rates the quality of life of CF suffers. Importantly, the quality of life for CF patients will increase topoint where they are able to work. The OmniSpirant system will, over time, be regarded as an essential weapon in thearmoury of health systems in the battle against other serious respiratory conditions affecting major patient populations suchas lung cancer and COPD, globally.The overall objective of our feasibility study is to demonstrate the potential value of the combined gene therapy systemmaturation based on a comprehensive analysis of the business concept in terms of technical, commercial and financialviability. The outcome of the study will be a full Business Plan that will feed into a Phase 2 project.